Pricing Log in Create free account
Friday 6 November 2026 Export FBIO’s income statement to Excel — free account

Fortress Biotech, Inc.

FBIO Healthcare Biotechnology

Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024.

Revenue
+14.0%
EPS
−116.0%
Free cash flow
−115.4%
Total debt
−35.7%

Quarter to June 2026, against a year earlier

1.85 0.01 +0.54%
Market cap
$61.4M
P/E
0.6×
Fwd P/E
0.8×
Dividend yield
—
F-score
5/9
Altman Z
−5.47
Beneish M
−0.01
Dividend safety
20/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 27.53%

Capital & Financial Ratios $m

Size
Market Cap 61.36
Revenue ttm 68.47
Net income ttm 141.19
Free cash flow ttm 125.84
Net debt Q (161.97)
Valuation
P/E 0.57
Forward P/E 0.75
Price / sales 0.86
Forward P/S Powerpack
Price / FCF 0.69
Price / book 0.29
Financial health
Current ratio Q 3.96 (at or above 1.5: strong)
Debt / equity Q 0.17 (at or below 0.5: strong)
Interest coverage Q (6.78)
Growth
Revenue growth Q +14.04% (above 0%: growing)
Operating income growth Q +72.57% (above 0%: growing)
EPS, this year +3,742.86% (at or above 15%: strong)
EPS, next year A −139.22% (below 0%: weak)
Revenue, next year A +24.55% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +9.86%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −1.5×, against a ten-year median of 0.5×; over the ten years it ranged from −3.6× in 2018 to 51.1× in 2016.
P/S against its own 10 years 21.78%
10-year low 10-year high
P/B against its own 10 years 0.09%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 81 57 79 197
Receivables 15 10 30 37
Inventory 10 14 10 8
Other — 1 — —
117 90 124 246
2023 2024 2025 Q'26
Payables 74 66 47 49
ST’ Debt — — — —
Other 5 2 0 0
85 71 50 62

Compound Annual Growth %

10y 5y 3y
Sales 53.64% 6.77% (5.83%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (2.99%) (20.60%) 7.52%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY25 Estimate 0.42 Actual −0.21

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY25 −0.44 −0.48 Miss by 0.04
Q2 FY25 −0.31 −0.46 Miss by 0.15
Q3 FY25 −0.43 0.11 Beat by 0.54
Q4 FY25 0.42 −0.21 Miss by 0.63

EPS $

Mar Jun Sep Dec Year
’26 2.82 (0.08) — — —
’25 (0.48) 0.45 0.11 (0.21) (0.07)
’24 (1.03) (0.73) (0.76) (0.61) (2.69)
’23 (3.15) (3.60) (0.94) (1.42) (8.47)
’22 (2.70) (3.60) (3.75) (4.50) (14.54)
’21 (1.65) (0.60) (3.90) (5.70) (11.84)
’20 (2.85) (2.85) (3.00) (0.90) (9.75)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 16 19 — — —
’25 13 16 18 16 63
’24 13 15 15 15 58
’23 12 17 35 20 85
’22 24 19 17 16 76
’21 12 18 21 18 69
’20 13 9 9 14 46
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 204 (59) — — —
’25 (20) (28) (6) (13) (66)
’24 (25) (22) (20) (13) (80)
’23 (43) (33) (17) (35) (128)
’22 (47) (41) (43) (48) (179)
’21 (22) (34) (22) (39) (117)
’20 (22) (17) (24) (20) (84)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 204 (59) — — —
’25 (18) (28) (6) (13) (65)
’24 (25) (22) (20) (28) (95)
’23 (43) (35) (17) (35) (130)
’22 (48) (42) (64) (48) (182)
’21 (22) (39) (29) (42) (133)
’20 (24) (20) (27) (22) (91)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 16 17 27 37 46 69 76 85 58 63 68 +16.1% 79 113 — +33.8%
Gross margin, % 95.21 78.79 77.22 71.25 67.99 53.36 59.37 72.91 63.80 66.92 65.59 (28.3) pt
EBT (71) (98) (131) (102) (103) (164) (213) (154) (121) (34) 146 (8.0%)
EBT margin, % (432.58) (565.46) (486.57) (277.54) (225.55) (238.92) (281.83) (181.79) (209.00) (53.01) 213.28 +379.6 pt
Net income (71) (100) (142) (102) (103) (165) (214) (154) (121) (33) 141 (8.2%)
Per share, $
Per share, $ Revenue 6.18 6.21 9.27 10.04 9.49 12.62 12.78 10.42 2.78 2.27 2.15 (10.5%)
Earnings (20.69) (24.14) (29.08) (10.94) (9.75) (11.84) (14.54) (8.47) (2.69) (0.07) 3.26 (46.9%)
Cash flow (17.19) (29.26) (34.10) (26.02) (17.42) (21.39) (30.28) (15.81) (3.86) (2.36) 3.96 (19.8%)
Capex (3.94) (1.44) (3.23) (2.57) (1.49) (3.00) (0.49) (0.26) (0.72) 0.04 0.00 n/m
Free cash flow (21.13) (30.70) (37.33) (28.60) (18.92) (24.39) (30.77) (16.07) (4.58) (2.32) 3.96 (21.8%)
Book value 31.13 43.37 6.81 19.88 41.02 41.45 8.44 0.20 (0.08) 2.23 6.48 (25.4%)
Shares, m 3 3 3 4 5 5 6 8 21 28 30 +29.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.57 0.0
P/S 6.79 9.84 1.39 3.84 5.01 2.97 0.76 0.26 0.73 1.61 0.86 3.3
P/B 1.35 1.41 1.89 1.94 1.16 0.90 1.15 13.77 0.00 1.64 0.29 2.5
EV/Sales 2.82 5.10 0.55 2.60 1.24 (0.79) (0.32) 0.13 0.90 1.25 (1.45) 1.3
EV/FCF (0.82) (1.03) (0.14) (0.90) (0.62) 0.41 0.12 (0.07) (0.44) (0.75) (1.16) (0.4)
Cash, $m
Cash, $m Operating cash flow (46) (81) (99) (95) (84) (117) (179) (128) (80) (66) 126 +4.1%
Capex (11) (4) (9) (9) (7) (16) (3) (2) (15) 1 0 n/m
Free cash flow (56) (85) (108) (104) (91) (133) (182) (130) (95) (65) 126 +1.5%
Balance, $m
Balance, $m Working capital 53 112 56 111 214 245 103 32 19 74 183 +3.8%
Net debt (63) (68) (4) (45) (167) (258) (82) (20) 1 (27) (162) (9.1%)
Shareholders’ equity 83 121 20 73 197 226 50 2 (2) 62 206 (3.2%)
Returns, %
Returns, % ROA (38.08) (32.10) (43.49) (21.75) (16.62) (17.73) (27.39) (29.74) (35.86) (1.14) 43.38 +36.9 pt
ROIC (210.59) (107.83) (464.85) (255.54) (197.50) 0.00 0.00 0.00 0.00 (124.61) (41.34) +86.0 pt
ROE (65.89) (65.74) (120.00) (86.61) (34.52) (30.60) (68.58) (266.13) 177,428.57 (6.22) 84.91 +59.7 pt
People
People Employees 45 68 88 93 111 173 187 186 101 78 — +6.3%
Revenue/emp, $m 0.37 0.25 0.31 0.39 0.41 0.40 0.41 0.45 0.57 0.81 — +9.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Fortress Biotech, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CSBR Champions Oncology, Inc. $66.3M — (loss-making) — (loss-making) +8.84% (above 0%: growing) n/m −198.74% (below 0%: shrinking) 50.54% (2.69%) Compare
CNXU Conexeu Sciences Inc. $65.4M — (loss-making) — — n/m −1,084.33% (below 0%: shrinking) — 0.00% Compare
CING Cingulate Inc. $61.7M — (loss-making) — — n/m −24.28% (below 0%: shrinking) 0.00% 0.00% Compare
FBIO Fortress Biotech, Inc. $61.4M 0.6× 0.8× +14.04% (above 0%: growing) n/m −115.37% (below 0%: shrinking) 67.18% (53.46%)
TENX Tenax Therapeutics, Inc. $61.0M — (loss-making) — −77.98% (below 0%: shrinking) n/m −125.93% (below 0%: shrinking) 0.00% 0.00% Compare
CGTX Cognition Therapeutics, Inc. $60.4M — (loss-making) — — n/m +45.35% (above 0%: growing) 0.00% 0.00% Compare
CRDF Cardiff Oncology, Inc. $58.8M — (loss-making) — (loss-making) −14.05% (below 0%: shrinking) n/m −41.36% (below 0%: shrinking) 100.00% (9,245.19%) Compare
TELO Telomir Pharmaceuticals, Inc. $57.5M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
CRBP Corbus Pharmaceuticals Holdings, Inc. $55.3M — (loss-making) — (loss-making) −92.09% (below 0%: shrinking) n/m −78.52% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $60.7M — — −46.02% — −61.93% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.89m 3.56m —
2024 1.38m 807.50k —
2023 1.12m (1.90m) —
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Fortress Biotech, Inc. (FBIO) Latest News

14 Aug

Impact 3 · · Moby transcript

13 Aug

Impact 3 · · The Motley Fool transcript
Impact 3 ·

12 Aug

Impact 3 · · MarketBeat transcript

27 Jul

Impact 4 ·

14 May

Impact 3 · · GlobeNewswire

13 May

Impact 3 · · GlobeNewswire

21 Apr

Impact 4 ·

31 Mar

Impact 4 · · GlobeNewswire

30 Mar

Impact 4 · · GlobeNewswire

25 Mar

Impact 3 · · GlobeNewswire

24 Feb

Impact 5 · · TipRanks

23 Feb

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswireMT Newswires
Impact 4 · · GlobeNewswire

18 Jan

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

13 Jan

Impact 4 · · GlobeNewswire

15 Dec

Impact 4 · · GlobeNewswire

14 Nov

Impact 4 · · ZacksZacksZacksZacksZacksZacksZacks
Impact 3 · · Associated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press Finance
Impact 3 ·

12 Nov

Impact 3 · · GlobeNewswire

24 Oct

Impact 3 · · GlobeNewswire

21 Oct

Impact 4 · · GlobeNewswireBioPharma DiveBioPharma DivePharmaceutical TechnologyMT NewswiresMT NewswiresMT NewswiresMT Newswires

1 Oct

Impact 4 · · MT Newswires
Impact 4 ·
Impact 4 · · GlobeNewswire
Impact 3 · · MT Newswires

2 Sep

Impact 3 ·

16 Aug

Impact 4 · · Simply Wall St.
stockrow.com/FBIO · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com